DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

AMEVIVE� Pregnancy Registry

Information source: Astellas Pharma Inc
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pregnancy

Intervention: Amevive exposure (Drug)

Phase: N/A

Status: Terminated

Sponsored by: Astellas Pharma Inc

Official(s) and/or principal investigator(s):
Vice President Medical Affairs, Study Director, Affiliation: Astellas Pharma Global Development


This is an observational, exposure-registration and follow-up study, to be conducted in the United States (US). The AMEVIVE Pregnancy Exposure Registry is designed to monitor pregnant subjects and fetuses exposed to AMEVIVE in order to detect any potential increase in the risk of major birth defects. The AMEVIVE Pregnancy Exposure Registry is sponsored by Astellas Pharma Global Development and will be managed by INC Research. The Registry will be monitored by an independent Advisory Committee of external experts in relevant specialties of teratology, epidemiology, maternal and fetal medicine, and infectious disease medicine (external member details available upon request).

Clinical Details

Official title: Assessment and Tracking of Long-Term Alefacept (LFA-3/IgG1 Fusion Protein) Pregnancy Exposure Registry

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: Evaluate pattern or increase in major birth defects in children of women w/ psoriasis who were exposed to AMEVIVE® at any time within the 8 wks prior to conception, or at any time during pregnancy, where outcome of the pregnancy is unknown prospectively

Secondary outcome:

To evaluate the number of live born infants versus fetal loss in pregnant women exposed to AMEVIVE®

To evaluate gestational age, body weight, gender, head circumference, and body length in live born infants exposed to AMEVIVE®

To evaluate appearance, pulse, grimace, activity, and respiration (APGAR) scores at 1 and 5 minutes of age in live born infants exposed to AMEVIVE®

To evaluate hospitalizations for infection in live born infants exposed to AMEVIVE®

To evaluate clinically significant infections with unusual organisms, not requiring hospitalization in live born infants exposed to AMEVIVE®

To evaluate malignancies in live born infants exposed to AMEVIVE®

Detailed description: Prospective reports will be collected from pregnant subjects, health care provider (HCP), or Astellas Product Safety Management staff. Data from the pregnant subjects will be collected at 4 to 5 months of pregnancy by telephone interviews with the Registry. The Registry will also contact the subject at 2 months and 12 months after the estimated delivery date (EDD) for post-natal & pediatric follow-up. The Registry will confirm the information collected from the subject with the HCP by telephone interviews with the Registry, forms mailed/faxed to the Registry, electronic forms/queries sent to the Registry, or a combination of these methods. If a live birth is reported, the infant's HCP will be contacted for the Pediatric Follow-Up at 2 months and 12 months of age. If a birth defect is reported, targeted follow-up will be conducted.


Minimum age: N/A. Maximum age: N/A. Gender(s): Female.


Inclusion Criteria:

- Have been exposed to AMEVIVE® within 8 weeks prior to conception or at any time

during pregnancy

- Provide sufficient information to determine that the pregnancy is prospectively

registered (i. e., the outcome of pregnancy must be unknown prospectively)

- Provide verbal consent to participate in the Registry, and

- Verbally provide the contact information for herself, her healthcare provider (HCP),

and the infant's HCP (if applicable) Exclusion Criteria:

- None

Locations and Contacts

INC Research, Wilmington, North Carolina 28405, United States
Additional Information

Link to Results on JAPIC

Starting date: December 2003
Last updated: December 10, 2013

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017